#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Eosinophils are a subset of granulocytes mostly known for their capacity to stimulate allergic reactions and to fight parasites .
2-1	16-27	Eosinophils	abstract	new	coref	2-3[3_0]
2-2	28-31	are	_	_	_	_
2-3	32-33	a	abstract[3]	giv[3]	coref	5-1[0_3]
2-4	34-40	subset	abstract[3]	giv[3]	_	_
2-5	41-43	of	abstract[3]	giv[3]	_	_
2-6	44-56	granulocytes	abstract[3]|abstract[4]	giv[3]|new[4]	ana	2-10[0_4]
2-7	57-63	mostly	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-8	64-69	known	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-9	70-73	for	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-10	74-79	their	abstract[3]|abstract[4]|abstract|abstract[6]	giv[3]|new[4]|giv|new[6]	_	_
2-11	80-88	capacity	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-12	89-91	to	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-13	92-101	stimulate	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-14	102-110	allergic	abstract[3]|abstract[4]|abstract[6]|event[7]	giv[3]|new[4]|new[6]|new[7]	_	_
2-15	111-120	reactions	abstract[3]|abstract[4]|abstract[6]|event[7]	giv[3]|new[4]|new[6]|new[7]	_	_
2-16	121-124	and	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-17	125-127	to	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-18	128-133	fight	abstract[3]|abstract[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-19	134-143	parasites	abstract[3]|abstract[4]|abstract[6]|animal	giv[3]|new[4]|new[6]|new	_	_
2-20	144-145	.	_	_	_	_

#Text=Under normal conditions , these cells are relatively rare representing 1 – 3 % of total white blood cells .
3-1	146-151	Under	_	_	_	_
3-2	152-158	normal	abstract[9]	new[9]	coref	4-2[13_9]
3-3	159-169	conditions	abstract[9]	new[9]	_	_
3-4	170-171	,	_	_	_	_
3-5	172-177	these	object[10]	new[10]	coref	3-16[12_10]
3-6	178-183	cells	object[10]	new[10]	_	_
3-7	184-187	are	_	_	_	_
3-8	188-198	relatively	_	_	_	_
3-9	199-203	rare	_	_	_	_
3-10	204-216	representing	_	_	_	_
3-11	217-218	1	abstract[11]	new[11]	_	_
3-12	219-220	–	abstract[11]	new[11]	_	_
3-13	221-222	3	abstract[11]	new[11]	_	_
3-14	223-224	%	abstract[11]	new[11]	_	_
3-15	225-227	of	abstract[11]	new[11]	_	_
3-16	228-233	total	abstract[11]|object[12]	new[11]|giv[12]	coref	5-19[25_12]
3-17	234-239	white	abstract[11]|object[12]	new[11]|giv[12]	_	_
3-18	240-245	blood	abstract[11]|object[12]	new[11]|giv[12]	_	_
3-19	246-251	cells	abstract[11]|object[12]	new[11]|giv[12]	_	_
3-20	252-253	.	_	_	_	_

#Text=During certain inflammatory conditions ( i.e. , allergies , parasitic infections , autoimmune diseases )
4-1	254-260	During	_	_	_	_
4-2	261-268	certain	abstract[13]	giv[13]	appos	4-6[14_13]
4-3	269-281	inflammatory	abstract[13]	giv[13]	_	_
4-4	282-292	conditions	abstract[13]	giv[13]	_	_
4-5	293-294	(	_	_	_	_
4-6	295-299	i.e.	abstract[14]|abstract[15]	giv[14]|giv[15]	appos|appos	4-6[15_14]|4-10[16_15]
4-7	300-301	,	abstract[14]|abstract[15]	giv[14]|giv[15]	_	_
4-8	302-311	allergies	abstract[14]|abstract[15]	giv[14]|giv[15]	_	_
4-9	312-313	,	abstract[15]	giv[15]	_	_
4-10	314-323	parasitic	abstract[15]|abstract[16]	giv[15]|giv[16]	appos	4-13[17_16]
4-11	324-334	infections	abstract[15]|abstract[16]	giv[15]|giv[16]	_	_
4-12	335-336	,	abstract[15]	giv[15]	_	_
4-13	337-347	autoimmune	abstract[15]|abstract[17]	giv[15]|giv[17]	_	_
4-14	348-356	diseases	abstract[15]|abstract[17]	giv[15]|giv[17]	_	_
4-15	357-358	)	_	_	_	_

#Text=eosinophils can rapidly increase , due to both de novo generation from bone marrow precursors and proliferation of tissue-resident cells , infiltrating inflamed tissues , including tumors .
5-1	359-370	eosinophils	abstract	giv	coref	8-4
5-2	371-374	can	_	_	_	_
5-3	375-382	rapidly	_	_	_	_
5-4	383-391	increase	_	_	_	_
5-5	392-393	,	_	_	_	_
5-6	394-397	due	_	_	_	_
5-7	398-400	to	_	_	_	_
5-8	401-405	both	event[20]	new[20]	_	_
5-9	406-408	de	object[19]|event[20]	new[19]|new[20]	_	_
5-10	409-413	novo	object[19]|event[20]	new[19]|new[20]	_	_
5-11	414-424	generation	event[20]	new[20]	_	_
5-12	425-429	from	event[20]	new[20]	_	_
5-13	430-434	bone	event[20]|object|plant[23]	new[20]|new|new[23]	coref	18-22
5-14	435-441	marrow	event[20]|animal|plant[23]	new[20]|new|new[23]	coref	18-21[139_0]
5-15	442-452	precursors	event[20]|plant[23]	new[20]|new[23]	_	_
5-16	453-456	and	_	_	_	_
5-17	457-470	proliferation	event[24]	new[24]	_	_
5-18	471-473	of	event[24]	new[24]	_	_
5-19	474-489	tissue-resident	event[24]|object[25]	new[24]|giv[25]	coref	10-43[65_25]
5-20	490-495	cells	event[24]|object[25]	new[24]|giv[25]	_	_
5-21	496-497	,	_	_	_	_
5-22	498-510	infiltrating	_	_	_	_
5-23	511-519	inflamed	object[26]	new[26]	coref	10-57[0_26]
5-24	520-527	tissues	object[26]	new[26]	_	_
5-25	528-529	,	object[26]	new[26]	_	_
5-26	530-539	including	object[26]	new[26]	_	_
5-27	540-546	tumors	object[26]|object	new[26]|new	coref	7-6[30_0]
5-28	547-548	.	_	_	_	_

#Text=Tumor-associated tissue
6-1	549-565	Tumor-associated	object[28]	new[28]	_	_
6-2	566-572	tissue	object[28]	new[28]	_	_

#Text=eosinophilia has been described in various solid tumors although its prognostic value in clinical oncology remains controversial .
7-1	573-585	eosinophilia	abstract	new	ana	7-10
7-2	586-589	has	_	_	_	_
7-3	590-594	been	_	_	_	_
7-4	595-604	described	_	_	_	_
7-5	605-607	in	_	_	_	_
7-6	608-615	various	object[30]	giv[30]	_	_
7-7	616-621	solid	object[30]	giv[30]	_	_
7-8	622-628	tumors	object[30]	giv[30]	_	_
7-9	629-637	although	_	_	_	_
7-10	638-641	its	abstract|abstract[32]	giv|new[32]	_	_
7-11	642-652	prognostic	abstract[32]	new[32]	_	_
7-12	653-658	value	abstract[32]	new[32]	_	_
7-13	659-661	in	abstract[32]	new[32]	_	_
7-14	662-670	clinical	abstract[32]|abstract[33]	new[32]|new[33]	_	_
7-15	671-679	oncology	abstract[32]|abstract[33]	new[32]|new[33]	_	_
7-16	680-687	remains	_	_	_	_
7-17	688-701	controversial	_	_	_	_
7-18	702-703	.	_	_	_	_

#Text=In vivo , eosinophils were shown to exert a protective role inhibiting tumor growth in mouse models of melanoma , colorectal cancer , hepatocellular carcinoma , and inducible fibrosarcoma .
8-1	704-706	In	_	_	_	_
8-2	707-711	vivo	abstract	new	coref	17-13
8-3	712-713	,	_	_	_	_
8-4	714-725	eosinophils	abstract	giv	coref	9-3
8-5	726-730	were	_	_	_	_
8-6	731-736	shown	_	_	_	_
8-7	737-739	to	_	_	_	_
8-8	740-745	exert	_	_	_	_
8-9	746-747	a	abstract[36]	new[36]	coref	22-21[168_36]
8-10	748-758	protective	abstract[36]	new[36]	_	_
8-11	759-763	role	abstract[36]	new[36]	_	_
8-12	764-774	inhibiting	abstract[36]	new[36]	_	_
8-13	775-780	tumor	abstract[36]|object|abstract[38]	new[36]|new|new[38]	coref|coref	15-19|20-7[150_38]
8-14	781-787	growth	abstract[36]|abstract[38]	new[36]|new[38]	_	_
8-15	788-790	in	abstract[36]	new[36]	_	_
8-16	791-796	mouse	abstract[36]|animal|abstract[40]	new[36]|new|new[40]	_	_
8-17	797-803	models	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-18	804-806	of	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-19	807-815	melanoma	abstract[36]|abstract[40]|abstract	new[36]|new[40]|new	coref	17-17
8-20	816-817	,	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-21	818-828	colorectal	abstract[36]|abstract[40]|abstract[42]	new[36]|new[40]|new[42]	coref	16-18[0_42]
8-22	829-835	cancer	abstract[36]|abstract[40]|abstract[42]	new[36]|new[40]|new[42]	_	_
8-23	836-837	,	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-24	838-852	hepatocellular	abstract[36]|abstract[40]|substance[43]	new[36]|new[40]|new[43]	coref	11-11[0_43]
8-25	853-862	carcinoma	abstract[36]|abstract[40]|substance[43]	new[36]|new[40]|new[43]	_	_
8-26	863-864	,	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-27	865-868	and	abstract[36]|abstract[40]	new[36]|new[40]	_	_
8-28	869-878	inducible	abstract[36]|abstract[40]|abstract[44]	new[36]|new[40]|new[44]	_	_
8-29	879-891	fibrosarcoma	abstract[36]|abstract[40]|abstract[44]	new[36]|new[40]|new[44]	_	_
8-30	892-893	.	_	_	_	_

#Text=Furthermore , eosinophils infiltration in the lung can prevent the formation of experimental pulmonary metastasis .
9-1	894-905	Furthermore	_	_	_	_
9-2	906-907	,	_	_	_	_
9-3	908-919	eosinophils	abstract|abstract[46]	giv|new[46]	coref	10-1
9-4	920-932	infiltration	abstract[46]	new[46]	_	_
9-5	933-935	in	abstract[46]	new[46]	_	_
9-6	936-939	the	abstract[46]|object[47]	new[46]|new[47]	coref	17-23[0_47]
9-7	940-944	lung	abstract[46]|object[47]	new[46]|new[47]	_	_
9-8	945-948	can	_	_	_	_
9-9	949-956	prevent	_	_	_	_
9-10	957-960	the	event[48]	new[48]	_	_
9-11	961-970	formation	event[48]	new[48]	_	_
9-12	971-973	of	event[48]	new[48]	_	_
9-13	974-986	experimental	event[48]|abstract[49]	new[48]|new[49]	coref	20-10[151_49]
9-14	987-996	pulmonary	event[48]|abstract[49]	new[48]|new[49]	_	_
9-15	997-1007	metastasis	event[48]|abstract[49]	new[48]|new[49]	_	_
9-16	1008-1009	.	_	_	_	_

#Text=Eosinophils are equipped with granules carrying a plethora of cytotoxic mediators , such as the cationic proteins major basic protein ( MBP ) , eosinophil cationic protein ( ECP ) , eosinophil peroxidase ( EPX ) , and granzymes ( granzyme-A in human cells , granzyme-B in murine cells ) that can destroy target cells or tissues .
10-1	1010-1021	Eosinophils	abstract	giv	coref	11-3
10-2	1022-1025	are	_	_	_	_
10-3	1026-1034	equipped	_	_	_	_
10-4	1035-1039	with	_	_	_	_
10-5	1040-1048	granules	object[51]	new[51]	coref	25-21[0_51]
10-6	1049-1057	carrying	object[51]	new[51]	_	_
10-7	1058-1059	a	object[51]|abstract[52]	new[51]|new[52]	_	_
10-8	1060-1068	plethora	object[51]|abstract[52]	new[51]|new[52]	_	_
10-9	1069-1071	of	object[51]|abstract[52]	new[51]|new[52]	_	_
10-10	1072-1081	cytotoxic	object[51]|abstract[52]|person[53]	new[51]|new[52]|new[53]	_	_
10-11	1082-1091	mediators	object[51]|abstract[52]|person[53]	new[51]|new[52]|new[53]	_	_
10-12	1092-1093	,	object[51]|abstract[52]|person[53]	new[51]|new[52]|new[53]	_	_
10-13	1094-1098	such	object[51]|abstract[52]|person[53]	new[51]|new[52]|new[53]	_	_
10-14	1099-1101	as	object[51]|abstract[52]|person[53]	new[51]|new[52]|new[53]	_	_
10-15	1102-1105	the	object[51]|abstract[52]|person[53]|substance[54]	new[51]|new[52]|new[53]|new[54]	appos	10-18[55_54]
10-16	1106-1114	cationic	object[51]|abstract[52]|person[53]|substance[54]	new[51]|new[52]|new[53]|new[54]	_	_
10-17	1115-1123	proteins	object[51]|abstract[52]|person[53]|substance[54]	new[51]|new[52]|new[53]|new[54]	_	_
10-18	1124-1129	major	substance[55]	giv[55]	appos	10-25[58_55]
10-19	1130-1135	basic	substance[55]	giv[55]	_	_
10-20	1136-1143	protein	substance[55]	giv[55]	_	_
10-21	1144-1145	(	_	_	_	_
10-22	1146-1149	MBP	abstract	new	_	_
10-23	1150-1151	)	_	_	_	_
10-24	1152-1153	,	_	_	_	_
10-25	1154-1164	eosinophil	abstract|substance[58]	new|giv[58]	coref	10-32
10-26	1165-1173	cationic	substance[58]	giv[58]	_	_
10-27	1174-1181	protein	substance[58]	giv[58]	_	_
10-28	1182-1183	(	_	_	_	_
10-29	1184-1187	ECP	abstract	new	_	_
10-30	1188-1189	)	_	_	_	_
10-31	1190-1191	,	_	_	_	_
10-32	1192-1202	eosinophil	abstract|substance[61]	giv|new[61]	coref	13-13
10-33	1203-1213	peroxidase	substance[61]	new[61]	_	_
10-34	1214-1215	(	_	_	_	_
10-35	1216-1219	EPX	abstract	new	_	_
10-36	1220-1221	)	_	_	_	_
10-37	1222-1223	,	_	_	_	_
10-38	1224-1227	and	_	_	_	_
10-39	1228-1237	granzymes	abstract[63]	new[63]	_	_
10-40	1238-1239	(	abstract[63]	new[63]	_	_
10-41	1240-1250	granzyme-A	abstract[63]|abstract[64]	new[63]|new[64]	coref	11-16[0_64]
10-42	1251-1253	in	abstract[63]|abstract[64]	new[63]|new[64]	_	_
10-43	1254-1259	human	abstract[63]|abstract[64]|object[65]	new[63]|new[64]|giv[65]	coref	10-48[68_65]
10-44	1260-1265	cells	abstract[63]|abstract[64]|object[65]	new[63]|new[64]|giv[65]	_	_
10-45	1266-1267	,	abstract[63]	new[63]	_	_
10-46	1268-1278	granzyme-B	abstract[63]|abstract[66]	new[63]|new[66]	_	_
10-47	1279-1281	in	abstract[63]|abstract[66]	new[63]|new[66]	_	_
10-48	1282-1288	murine	abstract[63]|abstract[66]|plant|object[68]	new[63]|new[66]|new|giv[68]	coref	10-54[69_68]
10-49	1289-1294	cells	abstract[63]|abstract[66]|object[68]	new[63]|new[66]|giv[68]	_	_
10-50	1295-1296	)	abstract[63]	new[63]	_	_
10-51	1297-1301	that	abstract[63]	new[63]	_	_
10-52	1302-1305	can	abstract[63]	new[63]	_	_
10-53	1306-1313	destroy	abstract[63]	new[63]	_	_
10-54	1314-1320	target	abstract[63]|object[69]|object[70]	new[63]|giv[69]|giv[70]	coref|coref	10-54[70_69]|11-9[75_70]
10-55	1321-1326	cells	abstract[63]|object[69]|object[70]	new[63]|giv[69]|giv[70]	_	_
10-56	1327-1329	or	abstract[63]|object[70]	new[63]|giv[70]	_	_
10-57	1330-1337	tissues	abstract[63]|object[70]|object	new[63]|giv[70]|giv	_	_
10-58	1338-1339	.	_	_	_	_

#Text=Indeed , eosinophils were shown to directly kill human colon carcinoma cells via release of granzyme-A in a mechanism dependent on the integrin CD11a/CD18 and on the cytokine IL-18 .
11-1	1340-1346	Indeed	_	_	_	_
11-2	1347-1348	,	_	_	_	_
11-3	1349-1360	eosinophils	abstract	giv	coref	12-4[82_0]
11-4	1361-1365	were	_	_	_	_
11-5	1366-1371	shown	_	_	_	_
11-6	1372-1374	to	_	_	_	_
11-7	1375-1383	directly	_	_	_	_
11-8	1384-1388	kill	_	_	_	_
11-9	1389-1394	human	object[75]	giv[75]	coref	12-16[88_75]
11-10	1395-1400	colon	animal|object[75]	new|giv[75]	_	_
11-11	1401-1410	carcinoma	substance|object[75]	giv|giv[75]	_	_
11-12	1411-1416	cells	object[75]	giv[75]	_	_
11-13	1417-1420	via	_	_	_	_
11-14	1421-1428	release	event[76]	new[76]	_	_
11-15	1429-1431	of	event[76]	new[76]	_	_
11-16	1432-1442	granzyme-A	event[76]|abstract	new[76]|giv	_	_
11-17	1443-1445	in	_	_	_	_
11-18	1446-1447	a	abstract[78]	new[78]	_	_
11-19	1448-1457	mechanism	abstract[78]	new[78]	_	_
11-20	1458-1467	dependent	abstract[78]	new[78]	_	_
11-21	1468-1470	on	abstract[78]	new[78]	_	_
11-22	1471-1474	the	abstract[78]|person[79]	new[78]|new[79]	coref	24-31[186_79]
11-23	1475-1483	integrin	abstract[78]|person[79]	new[78]|new[79]	_	_
11-24	1484-1494	CD11a/CD18	abstract[78]|person[79]	new[78]|new[79]	_	_
11-25	1495-1498	and	_	_	_	_
11-26	1499-1501	on	_	_	_	_
11-27	1502-1505	the	abstract[80]|abstract[81]	new[80]|new[81]	_	_
11-28	1506-1514	cytokine	abstract[80]|abstract[81]	new[80]|new[81]	_	_
11-29	1515-1520	IL-18	abstract[81]	new[81]	_	_
11-30	1521-1522	.	_	_	_	_

#Text=In addition , eosinophils activated by cross-linking of the receptor 2B4/CD244 exhibited tumoricidal activities against human B lymphoma cells .
12-1	1523-1525	In	_	_	_	_
12-2	1526-1534	addition	_	_	_	_
12-3	1535-1536	,	_	_	_	_
12-4	1537-1548	eosinophils	abstract[82]	giv[82]	coref	15-16[0_82]
12-5	1549-1558	activated	abstract[82]	giv[82]	_	_
12-6	1559-1561	by	abstract[82]	giv[82]	_	_
12-7	1562-1575	cross-linking	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-8	1576-1578	of	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-9	1579-1582	the	abstract[82]|abstract[83]|abstract[84]	giv[82]|new[83]|new[84]	_	_
12-10	1583-1591	receptor	abstract[82]|abstract[83]|abstract[84]	giv[82]|new[83]|new[84]	_	_
12-11	1592-1601	2B4/CD244	abstract[82]|abstract[83]|abstract[84]	giv[82]|new[83]|new[84]	_	_
12-12	1602-1611	exhibited	_	_	_	_
12-13	1612-1623	tumoricidal	abstract[85]	new[85]	coref	16-22[116_85]
12-14	1624-1634	activities	abstract[85]	new[85]	_	_
12-15	1635-1642	against	abstract[85]	new[85]	_	_
12-16	1643-1648	human	abstract[85]|object[88]	new[85]|giv[88]	coref	22-13[165_88]
12-17	1649-1650	B	abstract[85]|person|object[88]	new[85]|new|giv[88]	_	_
12-18	1651-1659	lymphoma	abstract[85]|abstract|object[88]	new[85]|new|giv[88]	_	_
12-19	1660-1665	cells	abstract[85]|object[88]	new[85]|giv[88]	_	_
12-20	1666-1667	.	_	_	_	_

#Text=It appears that the process of adhesion through integrins is important for eosinophil activation during inflammation .
13-1	1668-1670	It	abstract	giv	_	_
13-2	1671-1678	appears	_	_	_	_
13-3	1679-1683	that	_	_	_	_
13-4	1684-1687	the	abstract[90]	new[90]	_	_
13-5	1688-1695	process	abstract[90]	new[90]	_	_
13-6	1696-1698	of	abstract[90]	new[90]	_	_
13-7	1699-1707	adhesion	abstract[90]|abstract[91]	new[90]|new[91]	ana	14-3[0_91]
13-8	1708-1715	through	abstract[90]|abstract[91]	new[90]|new[91]	_	_
13-9	1716-1725	integrins	abstract[90]|abstract[91]|substance	new[90]|new[91]|new	_	_
13-10	1726-1728	is	_	_	_	_
13-11	1729-1738	important	_	_	_	_
13-12	1739-1742	for	_	_	_	_
13-13	1743-1753	eosinophil	abstract|event[94]	giv|new[94]	coref|coref	19-7|23-13[172_94]
13-14	1754-1764	activation	event[94]	new[94]	_	_
13-15	1765-1771	during	event[94]	new[94]	_	_
13-16	1772-1784	inflammation	event[94]|event	new[94]|new	_	_
13-17	1785-1786	.	_	_	_	_

#Text=However , it is unclear whether cell adhesion and degranulation are sequential or independent events .
14-1	1787-1794	However	_	_	_	_
14-2	1795-1796	,	_	_	_	_
14-3	1797-1799	it	abstract	giv	coref	14-7[98_0]
14-4	1800-1802	is	_	_	_	_
14-5	1803-1810	unclear	_	_	_	_
14-6	1811-1818	whether	_	_	_	_
14-7	1819-1823	cell	place|abstract[98]	new|giv[98]	coref	24-7
14-8	1824-1832	adhesion	abstract[98]	giv[98]	_	_
14-9	1833-1836	and	_	_	_	_
14-10	1837-1850	degranulation	event	new	coref	14-12[100_0]
14-11	1851-1854	are	_	_	_	_
14-12	1855-1865	sequential	event[100]	giv[100]	_	_
14-13	1866-1868	or	event[100]	giv[100]	_	_
14-14	1869-1880	independent	event[100]	giv[100]	_	_
14-15	1881-1887	events	event[100]	giv[100]	_	_
14-16	1888-1889	.	_	_	_	_

#Text=In addition , the mechanisms of granule protein secretion ( i.e. , degranulation ) in eosinophils leading to tumor cytotoxicity remain to be defined .
15-1	1890-1892	In	_	_	_	_
15-2	1893-1901	addition	_	_	_	_
15-3	1902-1903	,	_	_	_	_
15-4	1904-1907	the	abstract[101]	new[101]	coref	23-6[170_101]
15-5	1908-1918	mechanisms	abstract[101]	new[101]	_	_
15-6	1919-1921	of	abstract[101]	new[101]	_	_
15-7	1922-1929	granule	abstract[101]|abstract|substance[103]|abstract[104]	new[101]|new|new[103]|new[104]	appos|coref	15-11[105_104]|24-38
15-8	1930-1937	protein	abstract[101]|substance[103]|abstract[104]	new[101]|new[103]|new[104]	_	_
15-9	1938-1947	secretion	abstract[101]|abstract[104]	new[101]|new[104]	_	_
15-10	1948-1949	(	_	_	_	_
15-11	1950-1954	i.e.	abstract[105]	giv[105]	coref	25-18[198_105]
15-12	1955-1956	,	abstract[105]	giv[105]	_	_
15-13	1957-1970	degranulation	abstract[105]	giv[105]	_	_
15-14	1971-1972	)	_	_	_	_
15-15	1973-1975	in	_	_	_	_
15-16	1976-1987	eosinophils	abstract	giv	coref	18-6[134_0]
15-17	1988-1995	leading	_	_	_	_
15-18	1996-1998	to	_	_	_	_
15-19	1999-2004	tumor	object|abstract[108]	giv|new[108]	coref	16-30
15-20	2005-2017	cytotoxicity	abstract[108]	new[108]	_	_
15-21	2018-2024	remain	_	_	_	_
15-22	2025-2027	to	_	_	_	_
15-23	2028-2030	be	_	_	_	_
15-24	2031-2038	defined	_	_	_	_
15-25	2039-2040	.	_	_	_	_

#Text=IL-33 is an epithelial-derived “ alarmin ” playing multiple functions in Th2-related immunopathologies and recently implied in cancer immunity , exerting pro- or anti-tumoral activities , depending on the tumor type and microenvironmental factors .
16-1	2041-2046	IL-33	abstract	new	coref	16-3[110_0]
16-2	2047-2049	is	_	_	_	_
16-3	2050-2052	an	abstract[110]	giv[110]	coref	17-7[0_110]
16-4	2053-2071	epithelial-derived	abstract[110]	giv[110]	_	_
16-5	2072-2073	“	abstract[110]	giv[110]	_	_
16-6	2074-2081	alarmin	abstract[110]	giv[110]	_	_
16-7	2082-2083	”	abstract[110]	giv[110]	_	_
16-8	2084-2091	playing	abstract[110]	giv[110]	_	_
16-9	2092-2100	multiple	abstract[110]|abstract[111]	giv[110]|new[111]	coref	24-15[180_111]
16-10	2101-2110	functions	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
16-11	2111-2113	in	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
16-12	2114-2125	Th2-related	abstract[110]|abstract[111]|event|abstract[113]	giv[110]|new[111]|new|new[113]	_	_
16-13	2126-2143	immunopathologies	abstract[110]|abstract[111]|abstract[113]	giv[110]|new[111]|new[113]	_	_
16-14	2144-2147	and	abstract[110]	giv[110]	_	_
16-15	2148-2156	recently	abstract[110]	giv[110]	_	_
16-16	2157-2164	implied	abstract[110]	giv[110]	_	_
16-17	2165-2167	in	_	_	_	_
16-18	2168-2174	cancer	abstract|abstract[115]	giv|new[115]	coref	17-25[131_0]
16-19	2175-2183	immunity	abstract[115]	new[115]	_	_
16-20	2184-2185	,	_	_	_	_
16-21	2186-2194	exerting	_	_	_	_
16-22	2195-2199	pro-	abstract[116]	giv[116]	coref	25-7[194_116]
16-23	2200-2202	or	abstract[116]	giv[116]	_	_
16-24	2203-2215	anti-tumoral	abstract[116]	giv[116]	_	_
16-25	2216-2226	activities	abstract[116]	giv[116]	_	_
16-26	2227-2228	,	_	_	_	_
16-27	2229-2238	depending	_	_	_	_
16-28	2239-2241	on	_	_	_	_
16-29	2242-2245	the	abstract[118]	new[118]	_	_
16-30	2246-2251	tumor	object|abstract[118]	giv|new[118]	coref	17-1
16-31	2252-2256	type	abstract[118]	new[118]	_	_
16-32	2257-2260	and	_	_	_	_
16-33	2261-2279	microenvironmental	abstract[119]	new[119]	_	_
16-34	2280-2287	factors	abstract[119]	new[119]	_	_
16-35	2288-2289	.	_	_	_	_

#Text=Tumor over-expression or exogenous administration of IL-33 promotes anti-tumor immune responses in vivo in models of melanoma , acute myeloid leukemia , lung and colorectal cancer .
17-1	2290-2295	Tumor	object|abstract[121]	giv|new[121]	coref	20-7
17-2	2296-2311	over-expression	abstract[121]	new[121]	_	_
17-3	2312-2314	or	_	_	_	_
17-4	2315-2324	exogenous	event[122]	new[122]	_	_
17-5	2325-2339	administration	event[122]	new[122]	_	_
17-6	2340-2342	of	event[122]	new[122]	_	_
17-7	2343-2348	IL-33	event[122]|abstract	new[122]|giv	coref	18-1
17-8	2349-2357	promotes	_	_	_	_
17-9	2358-2368	anti-tumor	abstract[124]	new[124]	_	_
17-10	2369-2375	immune	abstract[124]	new[124]	_	_
17-11	2376-2385	responses	abstract[124]	new[124]	_	_
17-12	2386-2388	in	_	_	_	_
17-13	2389-2393	vivo	abstract	giv	coref	20-13
17-14	2394-2396	in	_	_	_	_
17-15	2397-2403	models	abstract[126]	new[126]	_	_
17-16	2404-2406	of	abstract[126]	new[126]	_	_
17-17	2407-2415	melanoma	abstract[126]|abstract	new[126]|giv	_	_
17-18	2416-2417	,	abstract[126]	new[126]	_	_
17-19	2418-2423	acute	abstract[126]|abstract[129]	new[126]|new[129]	_	_
17-20	2424-2431	myeloid	abstract[126]|place|abstract[129]	new[126]|new|new[129]	_	_
17-21	2432-2440	leukemia	abstract[126]|abstract[129]	new[126]|new[129]	_	_
17-22	2441-2442	,	abstract[126]	new[126]	_	_
17-23	2443-2447	lung	abstract[126]|object	new[126]|giv	coref	18-13[136_0]
17-24	2448-2451	and	abstract[126]	new[126]	_	_
17-25	2452-2462	colorectal	abstract[126]|abstract[131]	new[126]|giv[131]	coref	21-13[158_131]
17-26	2463-2469	cancer	abstract[126]|abstract[131]	new[126]|giv[131]	_	_
17-27	2470-2471	.	_	_	_	_

#Text=IL-33 drives substantial recruitment of eosinophils to inflamed sites , such as the lung , likely by promoting eosinophilopoiesis in the bone marrow .
18-1	2472-2477	IL-33	abstract	giv	coref	19-4
18-2	2478-2484	drives	_	_	_	_
18-3	2485-2496	substantial	event[133]	new[133]	_	_
18-4	2497-2508	recruitment	event[133]	new[133]	_	_
18-5	2509-2511	of	event[133]	new[133]	_	_
18-6	2512-2523	eosinophils	event[133]|abstract[134]	new[133]|giv[134]	coref	19-16[0_134]
18-7	2524-2526	to	event[133]|abstract[134]	new[133]|giv[134]	_	_
18-8	2527-2535	inflamed	event[133]|abstract[134]|place[135]	new[133]|giv[134]|new[135]	_	_
18-9	2536-2541	sites	event[133]|abstract[134]|place[135]	new[133]|giv[134]|new[135]	_	_
18-10	2542-2543	,	event[133]|abstract[134]|place[135]	new[133]|giv[134]|new[135]	_	_
18-11	2544-2548	such	event[133]|abstract[134]|place[135]	new[133]|giv[134]|new[135]	_	_
18-12	2549-2551	as	event[133]|abstract[134]|place[135]	new[133]|giv[134]|new[135]	_	_
18-13	2552-2555	the	event[133]|abstract[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
18-14	2556-2560	lung	event[133]|abstract[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
18-15	2561-2562	,	_	_	_	_
18-16	2563-2569	likely	_	_	_	_
18-17	2570-2572	by	_	_	_	_
18-18	2573-2582	promoting	_	_	_	_
18-19	2583-2601	eosinophilopoiesis	abstract	new	_	_
18-20	2602-2604	in	_	_	_	_
18-21	2605-2608	the	animal[139]	giv[139]	_	_
18-22	2609-2613	bone	object|animal[139]	giv|giv[139]	_	_
18-23	2614-2620	marrow	animal[139]	giv[139]	_	_
18-24	2621-2622	.	_	_	_	_

#Text=In addition , IL-33 can induce eosinophil superoxide anion production and promote the survival of eosinophils .
19-1	2623-2625	In	_	_	_	_
19-2	2626-2634	addition	_	_	_	_
19-3	2635-2636	,	_	_	_	_
19-4	2637-2642	IL-33	abstract	giv	coref	20-5
19-5	2643-2646	can	_	_	_	_
19-6	2647-2653	induce	_	_	_	_
19-7	2654-2664	eosinophil	abstract|substance[143]|abstract[144]	giv|new[143]|new[144]	coref	25-7
19-8	2665-2675	superoxide	substance|substance[143]|abstract[144]	new|new[143]|new[144]	_	_
19-9	2676-2681	anion	substance[143]|abstract[144]	new[143]|new[144]	_	_
19-10	2682-2692	production	abstract[144]	new[144]	_	_
19-11	2693-2696	and	_	_	_	_
19-12	2697-2704	promote	_	_	_	_
19-13	2705-2708	the	event[145]	new[145]	_	_
19-14	2709-2717	survival	event[145]	new[145]	_	_
19-15	2718-2720	of	event[145]	new[145]	_	_
19-16	2721-2732	eosinophils	event[145]|abstract	new[145]|giv	coref	22-5[162_0]
19-17	2733-2734	.	_	_	_	_

#Text=We initially reported that IL-33 inhibits tumor growth and pulmonary metastasis in vivo in an eosinophil-dependent manner .
20-1	2735-2737	We	person	acc	ana	22-1
20-2	2738-2747	initially	_	_	_	_
20-3	2748-2756	reported	_	_	_	_
20-4	2757-2761	that	_	_	_	_
20-5	2762-2767	IL-33	abstract	giv	coref	21-8
20-6	2768-2776	inhibits	_	_	_	_
20-7	2777-2782	tumor	object|abstract[150]	giv|giv[150]	coref	24-6
20-8	2783-2789	growth	abstract[150]	giv[150]	_	_
20-9	2790-2793	and	_	_	_	_
20-10	2794-2803	pulmonary	abstract[151]	giv[151]	_	_
20-11	2804-2814	metastasis	abstract[151]	giv[151]	_	_
20-12	2815-2817	in	_	_	_	_
20-13	2818-2822	vivo	abstract	giv	coref	24-23
20-14	2823-2825	in	_	_	_	_
20-15	2826-2828	an	abstract[153]	new[153]	coref	24-25[185_153]
20-16	2829-2849	eosinophil-dependent	abstract[153]	new[153]	_	_
20-17	2850-2856	manner	abstract[153]	new[153]	_	_
20-18	2857-2858	.	_	_	_	_

#Text=Subsequent studies confirmed eosinophil-mediated anti-tumoral effects of IL-33 in pre-clinical models of metastatic peritoneal cancer , hepatocellular , and prostatic cancer .
21-1	2859-2869	Subsequent	abstract[154]	new[154]	_	_
21-2	2870-2877	studies	abstract[154]	new[154]	_	_
21-3	2878-2887	confirmed	_	_	_	_
21-4	2888-2907	eosinophil-mediated	abstract[155]	new[155]	_	_
21-5	2908-2920	anti-tumoral	abstract[155]	new[155]	_	_
21-6	2921-2928	effects	abstract[155]	new[155]	_	_
21-7	2929-2931	of	abstract[155]	new[155]	_	_
21-8	2932-2937	IL-33	abstract[155]|abstract	new[155]|giv	coref	22-8
21-9	2938-2940	in	_	_	_	_
21-10	2941-2953	pre-clinical	abstract[157]	new[157]	_	_
21-11	2954-2960	models	abstract[157]	new[157]	_	_
21-12	2961-2963	of	abstract[157]	new[157]	_	_
21-13	2964-2974	metastatic	abstract[157]|abstract[158]	new[157]|giv[158]	coref	21-21[0_158]
21-14	2975-2985	peritoneal	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
21-15	2986-2992	cancer	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
21-16	2993-2994	,	abstract[157]	new[157]	_	_
21-17	2995-3009	hepatocellular	abstract[157]	new[157]	_	_
21-18	3010-3011	,	abstract[157]	new[157]	_	_
21-19	3012-3015	and	abstract[157]	new[157]	_	_
21-20	3016-3025	prostatic	abstract[157]	new[157]	_	_
21-21	3026-3032	cancer	abstract[157]|abstract	new[157]|giv	_	_
21-22	3033-3034	.	_	_	_	_

#Text=Our study suggested that eosinophils recruited by IL-33 might either function as accessory cells attracting CD8 T cells or play a direct antitumor role .
22-1	3035-3038	Our	person|abstract[161]	giv|new[161]	ana	23-3
22-2	3039-3044	study	abstract[161]	new[161]	_	_
22-3	3045-3054	suggested	_	_	_	_
22-4	3055-3059	that	_	_	_	_
22-5	3060-3071	eosinophils	abstract[162]	giv[162]	coref	23-11[0_162]
22-6	3072-3081	recruited	abstract[162]	giv[162]	_	_
22-7	3082-3084	by	abstract[162]	giv[162]	_	_
22-8	3085-3090	IL-33	abstract[162]|abstract	giv[162]|giv	coref	23-15
22-9	3091-3096	might	_	_	_	_
22-10	3097-3103	either	_	_	_	_
22-11	3104-3112	function	_	_	_	_
22-12	3113-3115	as	_	_	_	_
22-13	3116-3125	accessory	event|object[165]	new|giv[165]	coref	22-16[167_165]
22-14	3126-3131	cells	object[165]	giv[165]	_	_
22-15	3132-3142	attracting	object[165]	giv[165]	_	_
22-16	3143-3146	CD8	object[165]|abstract|object[167]	giv[165]|new|giv[167]	coref	25-23[201_167]
22-17	3147-3148	T	object[165]|object[167]	giv[165]|giv[167]	_	_
22-18	3149-3154	cells	object[165]|object[167]	giv[165]|giv[167]	_	_
22-19	3155-3157	or	_	_	_	_
22-20	3158-3162	play	_	_	_	_
22-21	3163-3164	a	abstract[168]	giv[168]	_	_
22-22	3165-3171	direct	abstract[168]	giv[168]	_	_
22-23	3172-3181	antitumor	abstract[168]	giv[168]	_	_
22-24	3182-3186	role	abstract[168]	giv[168]	_	_
22-25	3187-3188	.	_	_	_	_

#Text=Here , we further investigated the anti-tumoral mechanisms operated by eosinophils following activation with IL-33 .
23-1	3189-3193	Here	_	_	_	_
23-2	3194-3195	,	_	_	_	_
23-3	3196-3198	we	person	giv	ana	24-10
23-4	3199-3206	further	_	_	_	_
23-5	3207-3219	investigated	_	_	_	_
23-6	3220-3223	the	abstract[170]	giv[170]	_	_
23-7	3224-3236	anti-tumoral	abstract[170]	giv[170]	_	_
23-8	3237-3247	mechanisms	abstract[170]	giv[170]	_	_
23-9	3248-3256	operated	abstract[170]	giv[170]	_	_
23-10	3257-3259	by	abstract[170]	giv[170]	_	_
23-11	3260-3271	eosinophils	abstract[170]|abstract	giv[170]|giv	coref	24-18
23-12	3272-3281	following	abstract[170]	giv[170]	_	_
23-13	3282-3292	activation	abstract[170]|event[172]	giv[170]|giv[172]	_	_
23-14	3293-3297	with	abstract[170]|event[172]	giv[170]|giv[172]	_	_
23-15	3298-3303	IL-33	abstract[170]|event[172]|abstract	giv[170]|giv[172]|giv	coref	24-13
23-16	3304-3305	.	_	_	_	_

#Text=By using a panel of tumor cell lines , we show that IL-33 promotes tumoricidal functions of eosinophils in vitro and in vivo in a cell adhesion-dependent manner , through the integrin CD11b/CD18 and by inducing lytic granule convergence to the immune synapse .
24-1	3306-3308	By	_	_	_	_
24-2	3309-3314	using	_	_	_	_
24-3	3315-3316	a	person[174]	new[174]	_	_
24-4	3317-3322	panel	person[174]	new[174]	_	_
24-5	3323-3325	of	person[174]	new[174]	_	_
24-6	3326-3331	tumor	person[174]|object|object[177]	new[174]|giv|new[177]	coref	25-24
24-7	3332-3336	cell	person[174]|place|object[177]	new[174]|giv|new[177]	coref	24-26
24-8	3337-3342	lines	person[174]|object[177]	new[174]|new[177]	_	_
24-9	3343-3344	,	_	_	_	_
24-10	3345-3347	we	person	giv	ana	25-1
24-11	3348-3352	show	_	_	_	_
24-12	3353-3357	that	_	_	_	_
24-13	3358-3363	IL-33	abstract	giv	coref	25-12[195_0]
24-14	3364-3372	promotes	_	_	_	_
24-15	3373-3384	tumoricidal	abstract[180]	giv[180]	_	_
24-16	3385-3394	functions	abstract[180]	giv[180]	_	_
24-17	3395-3397	of	abstract[180]	giv[180]	_	_
24-18	3398-3409	eosinophils	abstract[180]|abstract	giv[180]|giv	_	_
24-19	3410-3412	in	abstract[180]	giv[180]	_	_
24-20	3413-3418	vitro	abstract[180]|abstract	giv[180]|new	_	_
24-21	3419-3422	and	_	_	_	_
24-22	3423-3425	in	_	_	_	_
24-23	3426-3430	vivo	abstract	giv	_	_
24-24	3431-3433	in	_	_	_	_
24-25	3434-3435	a	abstract[185]	giv[185]	_	_
24-26	3436-3440	cell	place|abstract[185]	giv|giv[185]	coref	25-15
24-27	3441-3459	adhesion-dependent	abstract[185]	giv[185]	_	_
24-28	3460-3466	manner	abstract[185]	giv[185]	_	_
24-29	3467-3468	,	_	_	_	_
24-30	3469-3476	through	_	_	_	_
24-31	3477-3480	the	person[186]	giv[186]	_	_
24-32	3481-3489	integrin	person[186]	giv[186]	_	_
24-33	3490-3500	CD11b/CD18	person[186]	giv[186]	_	_
24-34	3501-3504	and	_	_	_	_
24-35	3505-3507	by	_	_	_	_
24-36	3508-3516	inducing	_	_	_	_
24-37	3517-3522	lytic	event[188]	new[188]	_	_
24-38	3523-3530	granule	abstract|event[188]	giv|new[188]	_	_
24-39	3531-3542	convergence	event[188]	new[188]	_	_
24-40	3543-3545	to	event[188]	new[188]	_	_
24-41	3546-3549	the	event[188]|abstract[189]	new[188]|new[189]	_	_
24-42	3550-3556	immune	event[188]|abstract[189]	new[188]|new[189]	_	_
24-43	3557-3564	synapse	event[188]|abstract[189]	new[188]|new[189]	_	_
24-44	3565-3566	.	_	_	_	_

#Text=Our data provide mechanistic insights into eosinophil anti-tumor activities stimulated by IL-33 that involve cell contact and directional secretion of granules toward target tumor cells enhancing killing efficiency .
25-1	3567-3570	Our	person|abstract[191]	giv|new[191]	_	_
25-2	3571-3575	data	abstract[191]	new[191]	_	_
25-3	3576-3583	provide	_	_	_	_
25-4	3584-3595	mechanistic	abstract[192]	new[192]	_	_
25-5	3596-3604	insights	abstract[192]	new[192]	_	_
25-6	3605-3609	into	abstract[192]	new[192]	_	_
25-7	3610-3620	eosinophil	abstract[192]|abstract|abstract[194]	new[192]|giv|giv[194]	_	_
25-8	3621-3631	anti-tumor	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
25-9	3632-3642	activities	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
25-10	3643-3653	stimulated	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
25-11	3654-3656	by	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
25-12	3657-3662	IL-33	abstract[192]|abstract[194]|abstract[195]	new[192]|giv[194]|giv[195]	_	_
25-13	3663-3667	that	abstract[192]|abstract[194]|abstract[195]	new[192]|giv[194]|giv[195]	_	_
25-14	3668-3675	involve	abstract[192]|abstract[194]|abstract[195]	new[192]|giv[194]|giv[195]	_	_
25-15	3676-3680	cell	abstract[192]|abstract[194]|abstract[195]|place|event[197]	new[192]|giv[194]|giv[195]|giv|new[197]	_	_
25-16	3681-3688	contact	abstract[192]|abstract[194]|abstract[195]|event[197]	new[192]|giv[194]|giv[195]|new[197]	_	_
25-17	3689-3692	and	abstract[192]|abstract[194]|abstract[195]	new[192]|giv[194]|giv[195]	_	_
25-18	3693-3704	directional	abstract[192]|abstract[194]|abstract[195]|abstract[198]	new[192]|giv[194]|giv[195]|giv[198]	_	_
25-19	3705-3714	secretion	abstract[192]|abstract[194]|abstract[195]|abstract[198]	new[192]|giv[194]|giv[195]|giv[198]	_	_
25-20	3715-3717	of	abstract[192]|abstract[194]|abstract[195]|abstract[198]	new[192]|giv[194]|giv[195]|giv[198]	_	_
25-21	3718-3726	granules	abstract[192]|abstract[194]|abstract[195]|abstract[198]|object	new[192]|giv[194]|giv[195]|giv[198]|giv	_	_
25-22	3727-3733	toward	abstract[192]|abstract[194]|abstract[195]|abstract[198]	new[192]|giv[194]|giv[195]|giv[198]	_	_
25-23	3734-3740	target	abstract[192]|abstract[194]|abstract[195]|abstract[198]|object[201]	new[192]|giv[194]|giv[195]|giv[198]|giv[201]	_	_
25-24	3741-3746	tumor	abstract[192]|abstract[194]|abstract[195]|abstract[198]|object|object[201]	new[192]|giv[194]|giv[195]|giv[198]|giv|giv[201]	_	_
25-25	3747-3752	cells	abstract[192]|abstract[194]|abstract[195]|abstract[198]|object[201]	new[192]|giv[194]|giv[195]|giv[198]|giv[201]	_	_
25-26	3753-3762	enhancing	_	_	_	_
25-27	3763-3770	killing	abstract[202]	new[202]	_	_
25-28	3771-3781	efficiency	abstract[202]	new[202]	_	_
25-29	3782-3783	.	_	_	_	_
